1) LL.B, Monash University, Melbourne, Australia 2) Bachelor of Economics, Monash University, Melbourne, Australia
Working Experience
Leonard Ariff has been appointed as the Chief Executive Officer of CCM Duopharma Biotech Berhad since 1 January 2008 until to-date. On 9 January 2015, he was appointed the Group Managing Director of Chemical Company of Malaysia Berhad, a position he carries until to-date. He is also the Chief Executive Officer of the Pharmaceuticals Division of the CCM Group following an internal reorganisation of the CCM Group in January 2016. Prior to that, he was the Director of the Pharmaceuticals Division since January 2008. Leonard Ariff started his career in 1988 in various capacities in the legal profession before joining the CCM Group in 1990, where his main responsibilities were in business development and business management at CCM Chemicals Sdn. Bhd. In 2000, he assumed the position of Managing Director of Usaha Pharma (M) Sdn. Bhd. (formerly known as Prima Health Pharmacy (Retail) Sdn. Bhd.), CCM's pharmaceuticals retail arm. He later joined ICI Paints Malaysia Sdn. Bhd. in 2003 as the General Manager and was subsequently appointed as Managing Director in 2005 to 2007, before re-joining the CCM Group in 2008. He was also the Director of CCM'S Chemicals Division from October 2014 until December 2015. He holds directorships on the boards of Orica-CCM Energy Systems Sdn. Bhd., an associate company of Chemical Company of Malaysia Berhad and PanGen Biotech Inc. (Korea). He also acts in an advisory capacity at the International Medical University School of Pharmacy, Chair of the School of Business Advisory Board at Monash University Malaysia, Industrial and Community Advisory panel of Institute for Research in Molecular Medicine ("INFORMM") at University Sains Malaysia, and Committee Member of Good Governance for Medicines in the Ministry of Health, Malaysia. He is also a member of the Malaysian National Biotech Advisory Board.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....